{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-029903","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2023-08-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.979475+00:00","generated_at":"2026-06-11T05:15:40.034237+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Oncotelic JV Sapu starts registrational Phase 2b/3 trial of OT-101 in pancreatic cancer","bullets":["Sapu Bioscience (Oncotelic 45% JV partner) signed master services agreement with Cromos Pharma for OT-101 registrational trial.","Trial: Phase 2b/3 of TGF-β2 antisense OT-101 + FOLFIRINOX vs FOLFIRINOX alone in advanced/metastatic pancreatic cancer.","Multinational trial targeting up to 500 patients across USA, EU, and China.","Oncotelic CEO states TGFβ2 suppression may more than double survival in pancreatic cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-029903","json":"https://secwatch.observer/filing/0001493152-23-029903.json","markdown":"https://secwatch.observer/filing/0001493152-23-029903.md","text":"https://secwatch.observer/filing/0001493152-23-029903.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315223029903/0001493152-23-029903-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315223029903/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T05:15:40.034237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}